199 related articles for article (PubMed ID: 34094967)
1. Radiotherapy and Cytokine Storm: Risk and Mechanism.
Zhang C; Liang Z; Ma S; Liu X
Front Oncol; 2021; 11():670464. PubMed ID: 34094967
[TBL] [Abstract][Full Text] [Related]
2. Hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC): a short, safe, and effective postoperative regimen for high-risk breast cancer patients.
Koukourakis MI; Giatromanolaki A; Kouroussis C; Kakolyris S; Sivridis E; Frangiadaki C; Retalis G; Georgoulias V;
Int J Radiat Oncol Biol Phys; 2002 Jan; 52(1):144-55. PubMed ID: 11777632
[TBL] [Abstract][Full Text] [Related]
3. Accelerated Hypofractionated Radiotherapy Versus Stereotactic Body Radiotherapy for the Treatment of Stage I Nonsmall Cell Lung Cancer-A Single Institution Experience With Long-Term Follow-Up.
Karasawa K; Hayakawa S; Machitori Y; Shibata Y; Ogawa H; Ito K; Shimizuguchi T; Kawamoto T; Nihei K
Technol Cancer Res Treat; 2018 Jan; 17():1533033818806318. PubMed ID: 30317929
[TBL] [Abstract][Full Text] [Related]
4. Higher-than-expected severe (Grade 3-4) late urinary toxicity after postprostatectomy hypofractionated radiotherapy: a single-institution analysis of 1176 patients.
Cozzarini C; Fiorino C; Deantoni C; Briganti A; Fodor A; La Macchia M; Noris Chiorda B; Rancoita PM; Suardi N; Zerbetto F; Calandrino R; Montorsi F; Di Muzio N
Eur Urol; 2014 Dec; 66(6):1024-30. PubMed ID: 24985964
[TBL] [Abstract][Full Text] [Related]
5. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.
Widmark A; Gunnlaugsson A; Beckman L; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Fransson P; Tavelin B; Norman D; Zackrisson B; Anderson H; Kjellén E; Franzén L; Nilsson P
Lancet; 2019 Aug; 394(10196):385-395. PubMed ID: 31227373
[TBL] [Abstract][Full Text] [Related]
6. Theoretical effectiveness of cell survival in fractionated radiotherapy with hypoxia-targeted dose escalation.
Chvetsov AV; Rajendran JG; Zeng J; Patel SA; Bowen SR; Kim EY
Med Phys; 2017 May; 44(5):1975-1982. PubMed ID: 28236652
[TBL] [Abstract][Full Text] [Related]
7. Hypofractionated radiotherapy in non small cell lung cancer: a review of the current literature.
Beli I; Koukourakis G; Platoni K; Tolia M; Kelekis N; Kouvaris J; Syrigos C; Mystakidou K; Varveris C; Kouloulias V
Rev Recent Clin Trials; 2010 May; 5(2):103-11. PubMed ID: 20423316
[TBL] [Abstract][Full Text] [Related]
8. Abbreviated course of radiotherapy (RT) for breast cancer.
Schoenfeld JD; Harris JR
Breast; 2011 Oct; 20 Suppl 3():S116-27. PubMed ID: 22015277
[TBL] [Abstract][Full Text] [Related]
9. The impact of conventional or hypofractionated radiotherapy on voice quality and oncological outcome in patients with early glottic cancer.
Di Nicola L; Gravina GL; Marampon F; Bonfili P; Buonopane S; Di Staso M; Festuccia C; Franzese P; Tombolini M; Tombolini V
Oncol Rep; 2010 Nov; 24(5):1383-8. PubMed ID: 20878134
[TBL] [Abstract][Full Text] [Related]
10. Analysis of a large number of clinical studies for breast cancer radiotherapy: estimation of radiobiological parameters for treatment planning.
Guerrero M; Li XA
Phys Med Biol; 2003 Oct; 48(20):3307-26. PubMed ID: 14620060
[TBL] [Abstract][Full Text] [Related]
11. Accelerated hypofractionated adjuvant whole breast radiotherapy with concomitant photon boost after conserving surgery for early stage breast cancer: a prospective evaluation on 463 patients.
Cante D; Rosa La Porta M; Casanova-Borca V; Sciacero P; Girelli G; Pasquino M; Franco P; Ozzello F
Breast J; 2011; 17(6):586-93. PubMed ID: 21951485
[TBL] [Abstract][Full Text] [Related]
12. Designing equivalent treatment regimens for prostate radiotherapy based on equivalent uniform dose.
Li XA; Wang JZ; Stewart RD; Dibiase SJ; Wang D; Lawton CA
Br J Radiol; 2008 Jan; 81(961):59-68. PubMed ID: 18039721
[TBL] [Abstract][Full Text] [Related]
13. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial.
Incrocci L; Wortel RC; Alemayehu WG; Aluwini S; Schimmel E; Krol S; van der Toorn PP; Jager H; Heemsbergen W; Heijmen B; Pos F
Lancet Oncol; 2016 Aug; 17(8):1061-1069. PubMed ID: 27339116
[TBL] [Abstract][Full Text] [Related]
14. Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer.
Catton CN; Lukka H; Gu CS; Martin JM; Supiot S; Chung PWM; Bauman GS; Bahary JP; Ahmed S; Cheung P; Tai KH; Wu JS; Parliament MB; Tsakiridis T; Corbett TB; Tang C; Dayes IS; Warde P; Craig TK; Julian JA; Levine MN
J Clin Oncol; 2017 Jun; 35(17):1884-1890. PubMed ID: 28296582
[TBL] [Abstract][Full Text] [Related]
15. External beam radiation dose escalation for high grade glioma.
Khan L; Soliman H; Sahgal A; Perry J; Xu W; Tsao MN
Cochrane Database Syst Rev; 2016 Aug; (8):CD011475. PubMed ID: 27541334
[TBL] [Abstract][Full Text] [Related]
16. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
[TBL] [Abstract][Full Text] [Related]
17. Symptom palliation of hypofractionated radiotherapy for patients with incurable inflammatory breast cancer.
Choi HS; Jang HS; Kang KM; Choi BO
Radiat Oncol; 2019 Jun; 14(1):110. PubMed ID: 31221161
[TBL] [Abstract][Full Text] [Related]
18. Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a Phase III randomized trial.
Yeoh EE; Fraser RJ; McGowan RE; Botten RJ; Di Matteo AC; Roos DE; Penniment MG; Borg MF
Int J Radiat Oncol Biol Phys; 2003 Mar; 55(4):943-55. PubMed ID: 12605972
[TBL] [Abstract][Full Text] [Related]
19. The CD73/Ado System-A New Player in RT Induced Adverse Late Effects.
de Leve S; Wirsdörfer F; Jendrossek V
Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31623231
[TBL] [Abstract][Full Text] [Related]
20. Radiation therapy for Bowen's disease of the skin.
Lukas VanderSpek LA; Pond GR; Wells W; Tsang RW
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):505-10. PubMed ID: 16168842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
